Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New York, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Łukasz Sznajder, PhD, MSc, Assistant Professor, Department of Chemistry and Biochemistry,...
-
Presentation highlights Phase 1 trial completion, FDA Fast Track and Orphan Drug designations, and the expanding pipeline-in-a-product potential of TRE-515
-
PathMaker Neurosystems Board Director, John Donoghue, Ph.D., Awarded 2026 Queen Elizabeth Prize for Engineering
-
PathMaker Neurosystems Announces Completion of ALS Early Feasibility Study of the MyoRegulator Device for Non-Invasive Treatment of ALS
-
Athira Pharma, Inc. today announced that it has changed its name to LeonaBio, Inc.
-
First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates in ALS, FTD and traumatic brain injury.
-
Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants...
-
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing...
-
New York, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced more than $2.7 million in new research grants to advance groundbreaking discoveries across...
-
MIAMI, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BTT Medical Institute, in collaboration with btt Corp. (Brain Tunnelgenix Technologies Corp.), a medical technology company pioneering brain thermodynamics...